Aclaris Therapeutics股價因2a期臨床試驗積極結果大漲

英為財情

2025/07/30

Investing.com -- Aclaris Therapeutics Inc (NASDAQ:ACRS)股價在宣佈其ATI-2138治療中度至重度特應性皮炎的2a期臨床試驗取得積極頂線結果後，盤後交易中飆升20%。這家臨床階段生物製藥公司報告稱，該試驗達到了其目標，展示了良好的耐受性和臨床上顯著的疾病嚴重程度改善。研究涉及14名患者，他們接受了ATI-2138的低劑量治療，這是一種...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2555647460"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555647460\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555647460?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-30 05:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555647460","market":"hk","top_or_hot":-1,"title":"Aclaris Therapeutics股價因2a期臨床試驗積極結果大漲","media":"英為財情","content":"<div>\n<p>Investing.com --  Aclaris Therapeutics Inc  (NASDAQ:ACRS)股價在宣佈其ATI-2138治療中度至重度特應性皮炎的2a期臨床試驗取得積極頂線結果後，盤後交易中飆升20%。\n這家臨床階段生物製藥公司報告稱，該試驗達到了其目標，展示了良好的耐受性和臨床上顯著的疾病嚴重程度改善。研究涉及14名患者，他們接受了ATI-2138的低劑量治療，這是一種...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2908600\">網頁鏈接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclaris Therapeutics股價因2a期臨床試驗積極結果大漲</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclaris Therapeutics股價因2a期臨床試驗積極結果大漲\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">英為財情</strong><span class=\"h-time small\">2025-07-30 05:32</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Investing.com --  Aclaris Therapeutics Inc  (NASDAQ:ACRS)股價在宣佈其ATI-2138治療中度至重度特應性皮炎的2a期臨床試驗取得積極頂線結果後，盤後交易中飆升20%。\n這家臨床階段生物製藥公司報告稱，該試驗達到了其目標，展示了良好的耐受性和臨床上顯著的疾病嚴重程度改善。研究涉及14名患者，他們接受了ATI-2138的低劑量治療，這是一種...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2908600\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2908600\">英為財情</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2908600","article_id":"2555647460","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-93CH-2908600","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2555647460","pubTimestamp":1753824720,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com --  Aclaris Therapeutics Inc  股價在宣佈其ATI-2138治療中度至重度特應性皮炎的2a期臨床試驗取得積極頂線結果後，盤後交易中飆升20%。Aclaris首席執行官Neal Walker博士表示：\"這些2a期試驗結果是我們ITK項目的重大成就，它證實了該機制並佐證了我們在下一代ITK選擇性化合物上的工作。基於這些發現，Aclaris計劃進一步開發ATI-2138用於斑禿治療，同時探索與該藥物作用機制相關的其他適應症。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1141":"生命科学工具和服务","BK1583":"高瓴概念","03347":"泰格医药","BK4007":"制药","BK1576":"医药外包概念","ACRS":"Aclaris Therapeutics","BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Aclaris Therapeutics stock jumps on positive results from phase 2a clinical trial","themeId":"fb31d1870ba8f7b9af5b9c771a889cfe","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRS":1,"LENZ":1,"03347":1},"content_text":"Investing.com --  Aclaris Therapeutics Inc  (NASDAQ:ACRS)股價在宣佈其ATI-2138治療中度至重度特應性皮炎的2a期臨床試驗取得積極頂線結果後，盤後交易中飆升20%。\n這家臨床階段生物製藥公司報告稱，該試驗達到了其目標，展示了良好的耐受性和臨床上顯著的疾病嚴重程度改善。研究涉及14名患者，他們接受了ATI-2138的低劑量治療，這是一種選擇性口服抑制劑，靶向白細胞介素-2誘導性T細胞激酶(ITK)和Janus激酶3(JAK3)。\n結果顯示，濕疹面積和嚴重程度指數(EASI)有所改善，並且按照峯值瘙癢數字評分量表測量，經歷瘙癢嚴重程度減輕的患者百分比也有所增加。該公司強調，這些低劑量的療效結果與已獲批的JAK和IL-4/13抑制劑相當，但可能具有更好的耐受性。\nAclaris首席執行官Neal Walker博士表示：\"這些2a期試驗結果是我們ITK項目的重大成就，它證實了該機制並佐證了我們在下一代ITK選擇性化合物上的工作。\"\n藥效學結果驗證了ITK作為治療靶點的價值，顯示對關鍵炎症標誌物的強烈下調。基於這些發現，Aclaris計劃進一步開發ATI-2138用於斑禿治療，同時探索與該藥物作用機制相關的其他適應症。\n來自西奈山伊坎醫學院的Emma Guttman博士指出，該試驗的藥效學結果令人信服，特別是觀察到的抗炎活性以及ITK作為治療靶點的潛力。\n\n本文由人工智能協助翻譯。更多信息，請參見我們的使用條款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}